Synnovation Therapeutics Doses First Patient in Phase I Trial for PI3Kα Inhibitor SNV4818
Synnovation Therapeutics Doses First Patient in Phase I Trial for PI3Kα Inhibitor SNV4818 Synnovation Therapeutics Initiates Phase I Trial for SNV4818: A Potential Best-in-Class Pan-Mutant-Selective PI3Kα Inhibitor Introduction Synnovation Therapeutics,…
AN2 Shares Strategic Update on Phase 3 EBO-301 Trial for Treatment-Refractory MAC Lung Disease
AN2 Therapeutics Announces Strategic Update on Phase 3 EBO-301 Trial for Treatment-Refractory MAC Lung Disease AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing innovative small-molecule…
Latus Bio Presents Preclinical Data Supporting Its Huntington’s Disease Gene Therapy Program
Latus Bio Presents Preclinical Data Supporting Its Huntington’s Disease Gene Therapy Program Latus Bio, Inc. (Latus), a biotechnology company pioneering advancements in adeno-associated virus (AAV) gene therapy, is pleased to…
FDA Accepts sBLA for Opdivo® + Yervoy® in MSI-High/dMMR Cancers
FDA Accepts sBLA for Opdivo® + Yervoy® in MSI-High/dMMR Cancers U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with…
Revelation Biosciences, Inc. Secures Ongoing NASDAQ Listing Approval
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company dedicated to developing novel therapies aimed at rebalancing inflammation to optimize health, announced today that the…
Samsung Bioepis Launches PYZCHIVA® (ustekinumab-ttwe) Biosimilar to Stelara in the U.S.
Samsung Bioepis Co., Ltd. has announced the official U.S. launch of PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), expanding treatment options for patients with inflammatory conditions. This development marks a…
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort Following Successful Initial Results Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing…
Seaport Therapeutics Analyzes Trial Design and Placebo Response in MDD
Seaport Therapeutics Investigates Clinical Trial Design and Placebo Response in Major Depressive Disorder Studies Seaport Therapeutics (“Seaport” or “the Company”), a clinical-stage biopharmaceutical company focused on advancing innovative neuropsychiatric medicines,…
KalVista to Present New Sebetralstat Data at AAAAI 2025
KalVista Pharmaceuticals to Present New Sebetralstat Data at AAAAI/WAO 2025 Joint Congress KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage pharmaceutical company focused on developing oral therapies for rare diseases, has…
Go Reply & Sprint Reply Use AI to Automate Clinical Study Reports for Dr. Willmar Schwabe
Go Reply and Sprint Reply Automate Clinical Study Report Generation for Dr. Willmar Schwabe Using AI In a groundbreaking collaboration, Go Reply, a leading Google Cloud Premier Partner, and Sprint…
ReCerise Advances Collaboration for Hepatocellular Carcinoma Treatment
ReCerise and NCCS Forge Strategic Research Collaboration to Advance Hepatocellular Carcinoma Treatment ReCerise Therapeutics Inc. (“ReCerise”), a pioneering biotechnology company dedicated to the research and development of first-in-class oncology therapeutics,…
Sensorion Gets Positive Board Recommendation for SENS-501 Trial
Sensorion Gets Positive Board Recommendation for SENS-501 Trial Sensorion a pioneering clinical-stage biotechnology company specializing in the development of innovative therapies for hearing loss disorders, has announced a significant milestone…